Index
Introduction
Established in 2003, DiagnOptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device which can determine the tissue accumulation of AGEs in 30 seconds.
AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important risk predictor of diabetes and its complications.
Products
The introduction of the AGE Reader marks a technological breakthrough and has profound impact on the discovery and clinical intervention of diabetes and other ageing related chronic disorders. This innovative product not only enables instantaneous diagnosis and risk assessment on diabetes and its complications, but also provides clinicians with needed information to make correct treatment plan.
Since the CE certification on the AGE Reader in 2006, DiagnOptics has been selling this device to diverse end users in applicable markets. DiagnOptics recently introduced Diab-spot, a non-invasive test to identify people at risk for diabetes or pre-diabetes.
Currently the company is working on obtaining additional regulatory approvals in other regions and is engaged in new product development activities. The headoffice of DiagnOptics Technologies BV is in Groningen, the Netherlands.
Mission
DiagnOptics committed to the technological development and innovation in AGEs' detection through continuous dedication on non-invasive biomedical technologies.
Our mission is to improve the standard of clinical diagnosis and risk assessment on diabetes and its complications.
Management
|
|
Joined the company in June 2004, Mr. van den Berg is former general manager and co-founder of two pharmaceutical contract manufacturing companies and founder of VenGen BV, a life sciences start-up management company. He was trained in business economics at Tilburg University, the Netherlands. |
|
Dr. Smit founded DiagnOptics Technologies BV in 2003 and has been the medical director since 2004. He has been the head of the Vascular Unit of the University Medical Center Groningen for more than 15 years and has authored or co-authored over 200 scientific publications. He was trained in internal medicine and is associate professor in hypertension and atherosclerosis. |
|
|
|
Dr. Graaff founded DiagnOptics Technologies BV in 2003 and has been the technical director since 2004. He works within the Division for Artificial Organs in the Department of Biomedical Engineering at the University of Groningen. He was educated in applied physics and is specialized in biomedical optics. He wrote a thesis on tissue optics applied to reflectance pulse oximetry. |
Bart. A. van den Berg (Msc)
Dr. Andries J. Smit (MD, Phd)
Dr. Reindert Graaff (Phd)History
| 1995 | Dr. Smit and his co-workers made a coincidental finding of increased autofluorescence of the skin in many diabetes patients when they were performing fluorescein capillary leakage studies in diabetes. |
| 1996 | Dr. Smit and Dr. Graaff developed dedicated prototypes to assess skin autofluorescence in human |
| 1998 | The first clinical studies in diabetes and renal failure were started with an advanced prototype of the AGE Reader in the University Hospital Groningen, the Netherlands |
| 1999 | Filed patent application for the AGE Reader and published the first scientific report on the clinical use of AGE Reader prototype in diabetic patients |
| 2000 | Initiated the first large scale follow-up study in the Zwolle region |
| 2003 | Dr. Smit and Dr. Graaff founded DiagnOptics in Groningen, the Netherlands |
| 2004 | The first clinical study on AGE Reader were published in Diabetologia |
| 2005 | AGE Reader was first shown to future users (EASD, Athens 2005) |
| 2006 | AGE Reader received CE approval for commercialization in Europe |
| 2009 | AGE Reader CU (Compact Unit) received CE approval |
| 2010 | DiagnOptics received ISO 13485 certification for its Quality Management System |
| 2011 | Diab-spot was first shown to future users (Prediabetes, Madrid 2011) |
| 2011 | Diab-spot received CE approval |
Career
DiagnOptics is currently looking for a Technical Support Engineer to join our team.
Find a distributor in your country. If your country is not listed, please contact DiagnOptics for your enquiries: sales@diagnoptics.com
Our contact details
Diagnoptics Technologies B.V.
L.J. Zielstraweg 1
9713GX Groningen
The Netherlands
Tel: +31 (0)50 589 0612
Fax: +31 (0)50 589 0613
E-mail: info@diagnoptics.com
Follow us on Twitter
Follow us on LinkedIn
